Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection

{ 'indexed': {'date-parts': [[2023, 3, 7]], 'date-time': '2023-03-07T05:40:58Z', 'timestamp': 1678167658250}, 'reference-count': 45, 'publisher': 'Springer Science and Business Media LLC', 'license': [ { 'start': { 'date-parts': [[2023, 3, 7]], 'date-time': '2023-03-07T00:00:00Z', 'timestamp': 1678147200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2023, 3, 7]], 'date-time': '2023-03-07T00:00:00Z', 'timestamp': 1678147200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [ { 'DOI': '10.13039/100010664', 'name': 'H2020 Future and Emerging Technologies', 'doi-asserted-by': 'publisher', 'award': ['No 739593: HCEMM']}, { 'DOI': '10.13039/501100015498', 'name': 'Innovációs és Technológiai Minisztérium', 'doi-asserted-by': 'publisher', 'award': ['2020.1.16-Jövő-2021-00013']}, {'name': 'MTA-TKI Grant', 'award': ['Physical Virology Research Group']}, { 'DOI': '10.13039/501100002332', 'name': 'Semmelweis University', 'doi-asserted-by': 'crossref'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Ivermectin, an antiparasitic drug, has been ' 'repurposed for COVID-19 treatment during the SARS-CoV-2 pandemic. Although its antiviral ' 'efficacy was confirmed early in vitro and in preclinical studies, its clinical efficacy ' 'remained ambiguous. Our purpose was to assess the efficacy of ivermectin in terms of time to ' 'viral clearance based on the meta-analysis of available clinical trials at the closing date ' 'of the data search period, one year after the start of the pandemic. This meta-analysis was ' 'reported by following the PRISMA guidelines and by using the PICO format for formulating the ' 'question. The study protocol was registered on PROSPERO. Embase, MEDLINE (via PubMed), ' 'Cochrane Central Register of Controlled Trials (CENTRAL), bioRvix, and medRvix were searched ' 'for human studies of patients receiving ivermectin therapy with control groups. No language ' 'or publication status restrictions were applied. The search ended on 1/31/2021 exactly one ' 'year after WHO declared the public health emergency on novel coronavirus. The meta-analysis ' 'of three trials involving 382 patients revealed that the mean time to viral clearance was ' '5.74 days shorter in case of ivermectin treatment compared to the control groups [WMD = ' '−5.74, 95% CI (−11.1, −0.39), <jats:italic>p</jats:italic> = 0.036]. Ivermectin has ' 'significantly reduced the time to viral clearance in mild to moderate COVID-19 diseases ' 'compared to control groups. However, more eligible studies are needed for analysis to ' 'increase the quality of evidence of ivermectin use in COVID-19.</jats:p>', 'DOI': '10.1007/s11357-023-00756-y', 'type': 'journal-article', 'created': {'date-parts': [[2023, 3, 7]], 'date-time': '2023-03-07T01:02:16Z', 'timestamp': 1678150936000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 ' 'infection', 'prefix': '10.1007', 'author': [ {'given': 'Zsuzsanna', 'family': 'Ragó', 'sequence': 'first', 'affiliation': []}, {'given': 'Barbara', 'family': 'Tóth', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ágnes', 'family': 'Szalenko-Tőkés', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zsolt', 'family': 'Bella', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fanni', 'family': 'Dembrovszky', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nelli', 'family': 'Farkas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Szabolcs', 'family': 'Kiss', 'sequence': 'additional', 'affiliation': []}, {'given': 'Péter', 'family': 'Hegyi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mária', 'family': 'Matuz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Noémi', 'family': 'Tóth', 'sequence': 'additional', 'affiliation': []}, {'given': 'Imre', 'family': 'Hegedüs', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7343-0413', 'authenticated-orcid': False, 'given': 'Domokos', 'family': 'Máthé', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dezső', 'family': 'Csupor', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2023, 3, 7]]}, 'reference': [ { 'issue': '7', 'key': '756_CR1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(21)00270-8', 'volume': '9', 'author': 'P Venkatesan', 'year': '2021', 'unstructured': 'Venkatesan P. Repurposing drugs for treatment of COVID-19. Lancet Respir ' 'Med. 2021;9(7):e63. https://doi.org/10.1016/S2213-2600(21)00270-8.', 'journal-title': 'Lancet Respir Med.'}, { 'issue': '12', 'key': '756_CR2', 'doi-asserted-by': 'publisher', 'first-page': '984', 'DOI': '10.1038/nrmicro1048', 'volume': '2', 'author': 'S Õmura', 'year': '2004', 'unstructured': 'Õmura S, Crump A. The life and times of ivermectin—a success story. Nat ' 'Rev Microbiol. 2004;2(12):984–9.', 'journal-title': 'Nat Rev Microbiol.'}, { 'issue': '5', 'key': '756_CR3', 'doi-asserted-by': 'publisher', 'first-page': '3023', 'DOI': '10.21873/invivo.12134', 'volume': '34', 'author': 'S Lehrer', 'year': '2020', 'unstructured': 'Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike ' 'receptor-binding domain attached to ACE2. in vivo. 2020;34(5):3023–6.', 'journal-title': 'in vivo.'}, { 'issue': '3', 'key': '756_CR4', 'doi-asserted-by': 'publisher', 'first-page': '851', 'DOI': '10.1042/BJ20120150', 'volume': '443', 'author': 'KM Wagstaff', 'year': '2012', 'unstructured': 'Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is ' 'a specific inhibitor of importin α/β-mediated nuclear import able to ' 'inhibit replication of HIV-1 and dengue virus. Biochem J. ' '2012;443(3):851–6.', 'journal-title': 'Biochem J.'}, { 'issue': '4', 'key': '756_CR5', 'first-page': '246', 'volume': '12', 'author': 'AHD Janabi', 'year': '2020', 'unstructured': 'Janabi AHD. Effective anti-SARS-CoV-2 RNA dependent RNA polymerase drugs ' 'based on docking methods: the case of milbemycin, ivermectin, and ' 'baloxavir marboxil. Avicenna J Med Biotechnol. 2020;12(4):246.', 'journal-title': 'Avicenna J Med Biotechnol.'}, { 'issue': '5', 'key': '756_CR6', 'doi-asserted-by': 'publisher', 'first-page': '2217', 'DOI': '10.1080/07391102.2020.1839564', 'volume': '40', 'author': 'PS Sen Gupta', 'year': '2022', 'unstructured': 'Sen Gupta PS, Biswal S, Panda SK, Ray AK, Rana MK. Binding mechanism and ' 'structural insights into the identified protein target of COVID-19 and ' 'importin-α with in-vitro effective drug ivermectin. J Biomol Struct Dyn. ' '2022;40(5):2217–26.', 'journal-title': 'J Biomol Struct Dyn.'}, { 'issue': '7', 'key': '756_CR7', 'doi-asserted-by': 'publisher', 'first-page': '1153', 'DOI': '10.1007/s00210-020-01902-5', 'volume': '393', 'author': 'E Rizzo', 'year': '2020', 'unstructured': 'Rizzo E. Ivermectin, antiviral properties and COVID-19: a possible new ' 'mechanism of action. Naunyn Schmiedebergs Arch Pharmacol. ' '2020;393(7):1153–6.', 'journal-title': 'Naunyn Schmiedebergs Arch Pharmacol.'}, { 'issue': '12', 'key': '756_CR8', 'doi-asserted-by': 'publisher', 'first-page': '3209', 'DOI': '10.1038/s41418-020-00633-7', 'volume': '27', 'author': 'T Matsuyama', 'year': '2020', 'unstructured': 'Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT ' 'pathway is central to COVID-19. Cell Death & Diff. 2020;27(12):3209–25.', 'journal-title': 'Cell Death & Diff.'}, { 'issue': '6', 'key': '756_CR9', 'doi-asserted-by': 'publisher', 'first-page': '463', 'DOI': '10.1016/j.pt.2017.02.004', 'volume': '33', 'author': 'R Laing', 'year': '2017', 'unstructured': 'Laing R, Gillan V, Devaney E. Ivermectin - old drug, new tricks? Trends ' 'Parasitol. 2017;33(6):463–72. https://doi.org/10.1016/j.pt.2017.02.004.', 'journal-title': 'Trends Parasitol.'}, { 'key': '756_CR10', 'doi-asserted-by': 'publisher', 'unstructured': 'Draganov D, Han Z, Rana A, Bennett N, Irvine DJ, Lee PP. Ivermectin ' 'converts cold tumors hot and synergizes with immune checkpoint blockade ' 'for treatment of breast cancer. NPJ Breast Cancer. 2021;7(1):22.\xa0' 'https://doi.org/10.1038/s41523-021-00229-5.', 'DOI': '10.1038/s41523-021-00229-5'}, { 'issue': '10', 'key': '756_CR11', 'doi-asserted-by': 'publisher', 'first-page': '2536', 'DOI': '10.1080/10428194.2020.1786559', 'volume': '61', 'author': 'CG de Castro', 'year': '2020', 'unstructured': 'de Castro CG, Jr., Gregianin LJ, Burger JA. Continuous high-dose ' 'ivermectin appears to be safe in patients with acute myelogenous ' 'leukemia and could inform clinical repurposing for COVID-19 infection. ' 'Leuk Lymphoma. 2020;61(10):2536–7. ' 'https://doi.org/10.1080/10428194.2020.1786559.', 'journal-title': 'Leuk Lymphoma.'}, { 'key': '756_CR12', 'doi-asserted-by': 'crossref', 'unstructured': 'Arevalo AP, Pagotto R, Pórfido JL, Daghero H, Segovia M, Yamasaki K, et ' 'al. Ivermectin reduces in vivo coronavirus infection in a mouse ' 'experimental model. Scientific Rep. 2021;11(1):1-12.', 'DOI': '10.1038/s41598-021-86679-0'}, { 'issue': '8', 'key': '756_CR13', 'doi-asserted-by': 'publisher', 'DOI': '10.15252/emmm.202114122', 'volume': '13', 'author': 'GD de Melo', 'year': '2021', 'unstructured': 'de Melo GD, Lazarini F, Larrous F, Feige L, Kornobis E, Levallois S, et ' 'al. Attenuation of clinical and immunological outcomes during SARS-CoV-2 ' 'infection by ivermectin. EMBO Mol Med. 2021;13(8):e14122. ' 'https://doi.org/10.15252/emmm.202114122.', 'journal-title': 'EMBO Mol Med.'}, { 'issue': '9', 'key': '756_CR14', 'doi-asserted-by': 'publisher', 'first-page': '2100', 'DOI': '10.3390/cells9092100', 'volume': '9', 'author': 'DA Jans', 'year': '2020', 'unstructured': 'Jans DA, Wagstaff KM. Ivermectin as a broad-spectrum host-directed ' 'antiviral: the real deal? Cells. 2020;9(9):2100.', 'journal-title': 'Cells.'}, { 'key': '756_CR15', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2020.104787', 'volume': '178', 'author': 'L Caly', 'year': '2020', 'unstructured': 'Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ' 'ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral ' 'res. 2020;178:104787.', 'journal-title': 'Antiviral res.'}, { 'issue': '10', 'key': '756_CR16', 'doi-asserted-by': 'publisher', 'first-page': '1122', 'DOI': '10.1177/009127002237994', 'volume': '42', 'author': 'CA Guzzo', 'year': '2002', 'unstructured': 'Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et ' 'al. Safety, tolerability, and pharmacokinetics of escalating high doses ' 'of ivermectin in healthy adult subjects. The J of Clinical Pharma. ' '2002;42(10):1122–33.', 'journal-title': 'The J of Clinical Pharma.'}, { 'issue': '4', 'key': '756_CR17', 'doi-asserted-by': 'publisher', 'first-page': '827', 'DOI': '10.1093/jac/dkz524', 'volume': '75', 'author': 'M Navarro', 'year': '2020', 'unstructured': 'Navarro M, Camprubí D, Requena-Méndez A, Buonfrate D, Giorli G, Kamgno ' 'J, et al. Safety of high-dose ivermectin: a systematic review and ' 'meta-analysis. J Antimicrob Chemother. 2020;75(4):827–34.', 'journal-title': 'J Antimicrob Chemother.'}, { 'issue': '2', 'key': '756_CR18', 'doi-asserted-by': 'publisher', 'first-page': '382', 'DOI': '10.4269/ajtmh.17-0042', 'volume': '98', 'author': 'RE Chandler', 'year': '2018', 'unstructured': 'Chandler RE. Serious neurological adverse events after ivermectin—do ' 'they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg. ' '2018;98(2):382.', 'journal-title': 'Am J Trop Med Hyg.'}, { 'key': '756_CR19', 'unstructured': 'EMA advises against use of ivermectin for the prevention or treatment of ' 'COVID-19 outside randomised clinical trials. ' 'https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-prevention-treatment-COVID-19-outside-randomised-clinical-trials. ' '(2021). Accessed.'}, { 'key': '756_CR20', 'unstructured': 'Why you should not use ivermectin to treat or prevent COVID-19. ' 'https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-COVID-19 ' '(2021). Accessed.'}, { 'key': '756_CR21', 'unstructured': 'Merck statement on ivermectin use during the COVID-19 pandemic. ' 'https://www.merck.com/news/merck-statement-on-ivermectin-use-during-the-COVID-19-pandemic/. ' '(2021). Accessed.'}, { 'key': '756_CR22', 'doi-asserted-by': 'publisher', 'volume-title': 'Cochrane handbook for systematic reviews of interventions', 'author': 'JP Higgins', 'year': '2019', 'unstructured': 'Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. ' 'Cochrane handbook for systematic reviews of interventions: John Wiley & ' 'Sons; 2019.', 'DOI': '10.1002/9781119536604'}, { 'key': '756_CR23', 'doi-asserted-by': 'crossref', 'unstructured': 'Sterne J, Hernán M, Reeves B, Savović J, Berkman N, Viswanathan M. ' 'ROBINS-I: a tool for assessing risk of bias in non-randomised studies of ' 'interventions BMJ. 2016; 355: i4919. Int J Epidemiol. 2018;1.', 'DOI': '10.1136/bmj.i4919'}, { 'issue': '7650', 'key': '756_CR24', 'doi-asserted-by': 'publisher', 'first-page': '924', 'DOI': '10.1136/bmj.39489.470347.AD', 'volume': '336', 'author': 'GH Guyatt', 'year': '2008', 'unstructured': 'Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et ' 'al. GRADE: an emerging consensus on rating quality of evidence and ' 'strength of recommendations. Bmj. 2008;336(7650):924–6.', 'journal-title': 'Bmj.'}, { 'issue': '11', 'key': '756_CR25', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0242184', 'volume': '15', 'author': 'D Camprubí', 'year': '2020', 'unstructured': 'Camprubí D, Almuedo-Riera A, Martí-Soler H, Soriano A, Hurtado JC, ' 'Subirà C, et al. Lack of efficacy of standard doses of ivermectin in ' 'severe COVID-19 patients. PloS one. 2020;15(11):e0242184.', 'journal-title': 'PloS one.'}, { 'key': '756_CR26', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.eclinm.2020.100720', 'volume': '32', 'author': 'C Chaccour', 'year': '2021', 'unstructured': 'Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero ' 'A, Ruiz-Castillo P, et al. The effect of early treatment with ivermectin ' 'on viral load, symptoms and humoral response in patients with non-severe ' 'COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical ' 'trial. EClinicalMed. 2021;32:100720.', 'journal-title': 'EClinicalMed.'}, { 'issue': '11', 'key': '756_CR27', 'doi-asserted-by': 'publisher', 'first-page': '780', 'DOI': '10.1093/qjmed/hcab035', 'volume': '114', 'author': 'OE Babalola', 'year': '2021', 'unstructured': 'Babalola OE, Bode CO, Ajayi AA, Alakaloko FM, Akase IE, Otrofanowei E, ' 'et al. Ivermectin shows clinical benefits in mild to moderate COVID19: a ' 'randomized controlled double-blind, dose-response study in Lagos. QJM. ' '2021;114(11):780–8.', 'journal-title': 'QJM.'}, { 'key': '756_CR28', 'doi-asserted-by': 'publisher', 'first-page': '214', 'DOI': '10.1016/j.ijid.2020.11.191', 'volume': '103', 'author': 'S Ahmed', 'year': '2021', 'unstructured': 'Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A ' 'five-day course of ivermectin for the treatment of COVID-19 may reduce ' 'the duration of illness. Int J Infect Dis. 2021;103:214–6.', 'journal-title': 'Int J Infect Dis.'}, { 'issue': '12', 'key': '756_CR29', 'doi-asserted-by': 'publisher', 'first-page': '828', 'DOI': '10.1016/j.arbres.2020.08.007', 'volume': '56', 'author': 'MSI Khan', 'year': '2020', 'unstructured': 'Khan MSI, Khan MSI, Debnath CR, Nath PN, Al Mahtab M, Nabeka H, et al. ' 'Ivermectin treatment may improve the prognosis of patients with ' 'COVID-19. Arch Bronconeumol. 2020;56(12):828.', 'journal-title': 'Arch Bronconeumol.'}, { 'issue': '1', 'key': '756_CR30', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1186/s12879-021-06104-9', 'volume': '21', 'author': 'N Okumuş', 'year': '2021', 'unstructured': 'Okumuş N, Demirtürk N, Çetinkaya RA, Güner R, Avcı İY, Orhan S, et al. ' 'Evaluation of the effectiveness and safety of adding ivermectin to ' 'treatment in severe COVID-19 patients. BMC Infect Dis. 2021;21(1):1–11.', 'journal-title': 'BMC Infect Dis.'}, { 'key': '756_CR31', 'doi-asserted-by': 'publisher', 'first-page': '462', 'DOI': '10.18433/jpps31457', 'volume': '23', 'author': 'BM Padhy', 'year': '2020', 'unstructured': 'Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ' 'ivermectin as add on treatment in COVID 19: a systematic review and ' 'meta-analysis: Ivermectin in COVID-19: A meta-analysis. J Pharm Pharm ' 'Sci. 2020;23:462–9.', 'journal-title': 'J Pharm Pharm Sci.'}, { 'key': '756_CR32', 'doi-asserted-by': 'crossref', 'unstructured': 'Bartoszko JJ, Siemieniuk RA, Kum E, Qasim A, Zeraatkar D, Ge L, et al. ' 'Prophylaxis against covid-19: living systematic review and network ' 'meta-analysis. bmj. 2021:373.', 'DOI': '10.1136/bmj.n949'}, { 'issue': '4', 'key': '756_CR33', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.dsx.2021.102186', 'volume': '15', 'author': 'AFMZ Zein', 'year': '2021', 'unstructured': 'Zein AFMZ, Sulistiyana CS, Raffaelo WM, Pranata R. Ivermectin and ' 'mortality in patients with COVID-19: a systematic review, meta-analysis, ' 'and meta-regression of randomized controlled trials. Diabetes Metab ' 'Syndr. 2021;15(4):102186.', 'journal-title': 'Diabetes Metab Syndr.'}, { 'issue': '4', 'key': '756_CR34', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/MJT.0000000000001402', 'volume': '28', 'author': 'A Bryant', 'year': '2021', 'unstructured': 'Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, et al. ' 'Ivermectin for prevention and treatment of COVID-19 infection: a ' 'systematic review, meta-analysis, and trial sequential analysis to ' 'inform clinical guidelines. Am J Ther. 2021;28(4):e434.', 'journal-title': 'Am J Ther.'}, { 'issue': '12', 'key': '756_CR35', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pmed.1003501', 'volume': '17', 'author': 'MS Kim', 'year': '2020', 'unstructured': 'Kim MS, An MH, Kim WJ, Hwang T-H. Comparative efficacy and safety of ' 'pharmacological interventions for the treatment of COVID-19: a ' 'systematic review and network meta-analysis. PLoS med. ' '2020;17(12):e1003501.', 'journal-title': 'PLoS med.'}, { 'key': '756_CR36', 'doi-asserted-by': 'publisher', 'unstructured': 'Abd-Elsalam S, Noor RA, Badawi R, Khalaf M, Esmail ES, Soliman S, Abd El ' 'Ghafar MS, Elbahnasawy M, Moustafa EF, Hassany SM, Medhat MA, Ramadan ' 'HK, Eldeen MAS, Alboraie M, Cordie A, Esmat G. Clinical study evaluating ' 'the efficacy of ivermectin in COVID-19 treatment: A randomized ' 'controlled study. J Med Virol. 2021;93(10):5833–5838. ' 'https://doi.org/10.1002/jmv.27122.', 'DOI': '10.1002/jmv.27122'}, { 'issue': '14', 'key': '756_CR37', 'doi-asserted-by': 'publisher', 'first-page': '1426', 'DOI': '10.1001/jama.2021.3071', 'volume': '325', 'author': 'E López-Medina', 'year': '2021', 'unstructured': 'López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, ' 'Díazgranados JA, Oñate JM, Chavarriaga H, Herrera S, Parra B, Libreros ' 'G, Jaramillo R, Avendaño AC, Toro DF, Torres M, Lesmes MC, Rios CA, ' 'Caicedo I. Effect oilf ivermectin on time to resolution of symptoms ' 'among adults with md COVID-19: a randomized clinical trial. JAMA. ' '2021;325(14):1426–35. https://doi.org/10.1001/jama.2021.3071.', 'journal-title': 'JAMA.'}, { 'issue': '1', 'key': '756_CR38', 'doi-asserted-by': 'publisher', 'first-page': '635', 'DOI': '10.1186/s12879-021-06348-5', 'volume': '21', 'author': 'J Vallejos', 'year': '2021', 'unstructured': 'Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, ' 'Campias C, Chaparro Campias E, Medina MF, Achinelli F, Guglielmone HA, ' 'Ojeda J, Farizano Salazar D, Andino G, Kawerin P, Dellamea S, Aquino AC, ' 'Flores V, Martemucci CN, Martinez SM, Segovia JE, Reynoso PI, Sosa NC, ' 'Robledo ME, Guarrochena JM, Vernengo MM, Ruiz Diaz N, Meza E, Aguirre ' 'MG. Ivermectin to prevent hospitalizations in patients with COVID-19 ' '(IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. ' 'BMC Infect Dis. 2021;21(1):635. ' 'https://doi.org/10.1186/s12879-021-06348-5.', 'journal-title': 'BMC Infect Dis.'}, { 'issue': '12', 'key': '756_CR39', 'doi-asserted-by': 'publisher', 'first-page': '1743', 'DOI': '10.1016/j.jiac.2021.08.021', 'volume': '27', 'author': 'A Mohan', 'year': '2021', 'unstructured': 'Mohan A, Tiwari P, Suri TM, Mittal S, Patel A, Jain A, Velpandian T, Das ' 'US, Boppana TK, Pandey RM, Shelke SS, Singh AR, Bhatnagar S, Masih S, ' 'Mahajan S, Dwivedi T, Sahoo B, Pandit A, Bhopale S, Vig S, Gupta R, ' 'Madan K, Hadda V, Gupta N, Garg R, Meena VP, Guleria R. Single-dose oral ' 'ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre ' 'randomized, placebo-controlled trial. J Infect Chemother. ' '2021;27(12):1743–9. https://doi.org/10.1016/j.jiac.2021.08.021.', 'journal-title': 'J Infect Chemother.'}, { 'issue': '6', 'key': '756_CR40', 'doi-asserted-by': 'publisher', 'first-page': '989', 'DOI': '10.3390/v13060989', 'volume': '13', 'author': 'AA Samaha', 'year': '2021', 'unstructured': 'Samaha AA, Mouawia H, Fawaz M, Hassan H, Salami A, Bazzal AA, Saab HB, ' 'Al-Wakeel M, Alsaabi A, Chouman M, Moussawi MA, Ayoub H, Raad A, Hajjeh ' 'O, Eid AH, Raad H. Effects of a single dose of ivermectin on viral and ' 'clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: a pilot ' 'clinical trial in Lebanon. Viruses. 2021;13(6):989. ' 'https://doi.org/10.3390/v13060989.', 'journal-title': 'Viruses.'}, { 'issue': '2', 'key': '756_CR41', 'doi-asserted-by': 'publisher', 'first-page': '160', 'DOI': '10.3390/idr14020020', 'volume': '14', 'author': 'JL Beltran Gonzalez', 'year': '2022', 'unstructured': 'Beltran Gonzalez JL, González Gámez M, Mendoza Enciso EA, Esparza ' 'Maldonado RJ, Hernández Palacios D, Dueñas Campos S, Robles IO, Macías ' 'Guzmán MJ, García Díaz AL, Gutiérrez Peña CM, Martinez Medina L, Monroy ' 'Colin VA, Arreola Guerra JM. Efficacy and safety of ivermectin and ' 'Hydroxychloroquine in patients with severe COVID-19: a randomized ' 'controlled trial. Infect Dis Rep. 2022;14(2):160–8. ' 'https://doi.org/10.3390/idr14020020.', 'journal-title': 'Infect Dis Rep'}, { 'key': '756_CR42', 'doi-asserted-by': 'publisher', 'unstructured': 'Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso ' 'DF, et al. Corrigendum to Antiviral effect of high-dose ivermectin in ' 'adults with COVID-19: a proof-of-concept randomized trial. ' 'EClinicalMedicine. 2021;37:100959. ' 'https://doi.org/10.1016/j.eclinm.2021.100959.', 'DOI': '10.1016/j.eclinm.2021.100959'}, { 'key': '756_CR43', 'doi-asserted-by': 'publisher', 'first-page': '733', 'DOI': '10.1016/j.ijid.2022.07.003', 'volume': '122', 'author': 'A Biber', 'year': '2022', 'unstructured': 'Biber A, Harmelin G, Lev D, Ram L, Shaham A, Nemet I, et al. The effect ' 'of ivermectin on the viral load and culture viability in early treatment ' 'of nonhospitalized patients with mild COVID-19 - a double-blind, ' 'randomized placebo-controlled trial. Int J Infect Dis. 2022;122:733–40. ' 'https://doi.org/10.1016/j.ijid.2022.07.003.', 'journal-title': 'Int J Infect Dis.'}, { 'issue': '16', 'key': '756_CR44', 'doi-asserted-by': 'publisher', 'first-page': '1595', 'DOI': '10.1001/jama.2022.18590', 'volume': '328', 'author': 'S Naggie', 'year': '2022', 'unstructured': 'Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Gentile N, Collins S, et ' 'al. Effect of ivermectin vs placebo on time to sustained recovery in ' 'outpatients with mild to moderate COVID-19: a randomized clinical trial. ' 'JAMA. 2022;328(16):1595–603. https://doi.org/10.1001/jama.2022.18590.', 'journal-title': 'JAMA.'}, { 'key': '756_CR45', 'doi-asserted-by': 'publisher', 'unstructured': 'Kerr L, Cadegiani FA, Baldi F, Lobo RB, Assagra WLO, Proença FC, et al. ' 'Corrected: Ivermectin Prophylaxis Used for COVID-19: A Citywide, ' 'Prospective, Observational Study of 223,128 Subjects Using Propensity ' 'Score Matching. Cureus. 2022;14(3):c6. ' 'https://doi.org/10.7759/cureus.c61.', 'DOI': '10.7759/cureus.c61'}], 'container-title': 'GeroScience', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s11357-023-00756-y.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s11357-023-00756-y/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s11357-023-00756-y.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 3, 7]], 'date-time': '2023-03-07T01:08:14Z', 'timestamp': 1678151294000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s11357-023-00756-y'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 3, 7]]}, 'references-count': 45, 'alternative-id': ['756'], 'URL': 'http://dx.doi.org/10.1007/s11357-023-00756-y', 'relation': {}, 'ISSN': ['2509-2715', '2509-2723'], 'subject': ['Geriatrics and Gerontology', 'Aging'], 'container-title-short': 'GeroScience', 'published': {'date-parts': [[2023, 3, 7]]}, 'assertion': [ { 'value': '11 November 2022', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '16 February 2023', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '7 March 2023', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'Not applicable.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Institutional review board statement'}}, { 'value': 'Not applicable.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Informed consent statement'}}, { 'value': 'The authors declare no competing interests.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}]}